# Table of Contents

1. Header
2. Abstract
3. Plain Language Summary
4. Summary of Findings for the Main Comparison
5. Background
6. Objectives
7. Methods
8. Results
9. Figure 1.
10. Figure 2.
11. Figure 3.
12. Additional Summary of Findings
13. Discussion
14. Authors' Conclusions
15. Acknowledgements
16. References
17. Characteristics of Studies
18. Data and Analyses
19. Analysis 1.1. Comparison 1 Metformin versus megestrol acetate, Outcome 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as atrophic or proliferative endometrium).
20. Analysis 1.2. Comparison 1 Metformin versus megestrol acetate, Outcome 2 Progression of endometrial hyperplasia to endometrial cancer.
21. Analysis 1.3. Comparison 1 Metformin versus megestrol acetate, Outcome 3 Hysterectomy rate.
22. Analysis 1.4. Comparison 1 Metformin versus megestrol acetate, Outcome 4 Abnormal uterine bleeding.
23. Analysis 2.1. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as proliferative/secretory endometrium).
25. Analysis 2.3. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 3 Progression of endometrial hyperplasia to endometrial cancer.
26. Analysis 2.4. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 4 Hysterectomy rate.
27. Appendices
28. Contributions of Authors
29. Declarations of Interest
30. Sources of Support
31. Differences Between Protocol and Review
Metformin for endometrial hyperplasia

Naomi S Clement1, Thomas RW Oliver2, Hunain Shiwani3, Juliane RF Sanner4, Caroline A Mulvaney5, William Atiomo4

1Faculty of Health Sciences and Medicine, University of Nottingham, Nottingham, UK. 2Department of Histopathology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 3Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 4Faculty of Health Sciences and Medicine, The University of Nottingham, Nottingham, UK. 5School of Medicine, University of Nottingham, Nottingham, UK

Contact address: Naomi S Clement, Faculty of Health Sciences and Medicine, University of Nottingham, Queen’s Medical Centre, Derby Road, Nottingham, NG7 2UH, UK. mzynsc@nottingham.ac.uk.

Editorial group: Cochrane Gynaecology and Fertility Group.

Citation: Clement NS, Oliver TRW, Shiwani H, Sanner JRF, Mulvaney CA, Atiomo W. Metformin for endometrial hyperplasia. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD012214. DOI: 10.1002/14651858.CD012214.pub2.

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Endometrial cancer is one of the most common gynaecological cancers in the world. Rates of endometrial cancer are rising, in part because of rising obesity rates. Endometrial hyperplasia is a precancerous condition in women that can lead to endometrial cancer if left untreated. Endometrial hyperplasia occurs more commonly than endometrial cancer. Progesterone tablets currently used to treat women with endometrial hyperplasia are associated with adverse effects in up to 84% of women. The levonorgestrel intrauterine device (Mirena Coil, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA) may improve compliance, but it is invasive, is not acceptable to all women, and is associated with irregular vaginal bleeding in 82% of cases. Therefore, an alternative treatment for women with endometrial hyperplasia is needed. Metformin, a drug that is often used to treat people with diabetes, has been shown in some human studies to reverse endometrial hyperplasia. However, the effectiveness and safety of metformin for treatment of endometrial hyperplasia remain uncertain.

Objectives

To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia.

Search methods

We searched the Cochrane Gynaecology and Fertility Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, Google Scholar, OpenGrey, Latin American Caribbean Health Sciences Literature (LILACS), and two trials registers from inception to 10 January 2017. We searched the bibliographies of all included studies and reviews on this topic. We also handsearched the conference abstracts of the European Society of Human Reproduction and Embryology (ESHRE) 2015 and the American Society for Reproductive Medicine (ASRM) 2015.

Selection criteria

We included randomised controlled trials (RCTs) and cross-over trials comparing metformin (used alone or in combination with other medical therapies) versus placebo or no treatment, any conventional medical treatment, or any other active intervention for women with histologically confirmed endometrial hyperplasia of any type.
Data collection and analysis

Two review authors independently assessed studies for eligibility, extracted data from included studies, and assessed the risk of bias of included studies. We resolved disagreements by discussion or by deferment to a third review author. When study details were missing, review authors contacted study authors. The primary outcome of this review was regression of endometrial hyperplasia histology (with or without atypia) towards normal histology. Secondary outcome measures included recurrence of endometrial hyperplasia, progression of endometrial hyperplasia to endometrial cancer, hysterectomy rate, abnormal uterine bleeding, health-related quality of life, and adverse effects during treatment.

Main results

We included three RCTs in which a total of 77 women took part. We rated the quality of the evidence as very low for all outcomes owing to very serious risk of bias (associated with poor reporting, attrition, and limitations in study design) and imprecision.

We performed a meta-analysis of two trials with 59 participants. When metformin was compared with megestrol acetate in women with endometrial hyperplasia, we found insufficient evidence to determine whether there were differences between groups for the following outcomes: regression of endometrial hyperplasia histology towards normal histology (odds ratio (OR) 3.34, 95% confidence interval (CI) 0.97 to 11.57, two RCTs, n = 59, very low-quality evidence), hysterectomy rates (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 59, very low-quality evidence), and rates of abnormal uterine bleeding (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 44, very low-quality evidence). We found no data for recurrence of endometrial hyperplasia or health-related quality of life. Both studies (n = 59) provided data on progression of endometrial hyperplasia to endometrial cancer as well as one (n = 16) reporting some adverse effects in the metformin arm, notably nausea, thrombosis, lactic acidosis, abnormal liver and renal function among others.

Another trial including 16 participants compared metformin plus megestrol acetate versus megestrol acetate alone in women with endometrial hyperplasia. We found insufficient evidence to determine whether there were differences between groups for the following outcomes: regression of endometrial hyperplasia histology towards normal histology (OR 9.00, 95% CI 0.94 to 86.52, one RCT, n = 16, very low-quality evidence), recurrence of endometrial hyperplasia among women who achieve regression (OR not estimable, no events recorded, one RCT, n = 8, very low-quality evidence), progression of endometrial hyperplasia to endometrial cancer (OR not estimable, no events recorded, one RCT, n = 13, very low-quality evidence), or hysterectomy rates (OR 0.29, 95% CI 0.01 to 8.37, one RCT, n = 16, very low-quality evidence). Investigators provided no data on abnormal uterine bleeding or health-related quality of life. In terms of adverse effects, three of eight participants (37.5%) in the metformin plus megestrol acetate study arm reported nausea.

Authors’ conclusions

At present, evidence is insufficient to support or refute the use of metformin alone or in combination with standard therapy - specifically, megestrol acetate - versus megestrol acetate alone, for treatment of endometrial hyperplasia. Robustly designed and adequately powered randomised controlled trials yielding long-term outcome data are needed to address this clinical question.

Plain Language Summary

Metformin for endometrial hyperplasia

Review question

Is metformin an effective and safe treatment for people with endometrial hyperplasia?

Background

Endometrial cancer (cancer of the lining of the womb) is a common cancer that affects the reproductive organs in women worldwide. Endometrial hyperplasia is a precancerous condition in women that can lead to endometrial cancer, if left untreated. Successful treatment of women with endometrial hyperplasia can prevent endometrial cancer. Endometrial hyperplasia is usually treated by providing progesterone hormone tablets, inserting the levonorgestrel intrauterine system (Mirena Coil) into the womb, advising overweight women to lose weight, or performing a hysterectomy for women who do not want any future pregnancy. However, progesterone tablets are associated with side effects in up to 84% of women, and this can prevent women from completing treatment. Also, progesterone tablets do not always work, and endometrial hyperplasia can return in up to 14% to 30% of women after treatment. The Mirena Coil is associated with irregular vaginal bleeding in up to 82% of women, and many women find it painful to use or otherwise unacceptable. Therefore, an alternative treatment for endometrial hyperplasia is required. Metformin, an oral tablet that usually is used to treat
diabetes, has been shown to cure endometrial hyperplasia in some human studies. Although people taking metformin may experience side effects, treatment is usually well tolerated. If women experience fewer side effects when taking metformin rather than progesterone tablets, and if metformin effectively treats endometrial hyperplasia, then compliance will be better and the cure rate will improve. This could reduce the number of women who end up with endometrial cancer. However, the effectiveness and safety of metformin used to treat women with endometrial hyperplasia remain uncertain.

Study characteristics

We included three randomised controlled trials in which a total of 77 women took part. Two studies compared metformin versus megestrol acetate (a form of progesterone), and one study compared metformin plus megestrol acetate versus megestrol acetate alone. Women in all studies received treatment for approximately 12 weeks. The evidence is current to 10 January 2017.

Key results

Comparisons of metformin versus megestrol acetate have provided insufficient evidence to show differences in effectiveness for curing endometrial hyperplasia. It remains uncertain whether there is any difference between metformin and megestrol acetate in reducing hysterectomy rates or abnormal uterine bleeding in women with endometrial hyperplasia. Although both studies provided data on progression of endometrial hyperplasia to endometrial cancer, there were no events in either arm, and study authors reported no data on adverse effects.

When metformin plus megestrol acetate is compared with megestrol acetate, differences in effectiveness between groups treating endometrial hyperplasia remain unclear. Three of eight patients in the metformin plus megestrol acetate study arm reported nausea. Occurrence of other adverse events is unclear.

Quality of the evidence

We rated the quality of evidence as very low for all outcomes owing to very serious risk of bias (associated with poor reporting, attrition, and limitations in study design) and imprecision.
### Summary of Findings for the Main Comparison

**Metformin compared with megestrol acetate for endometrial hyperplasia**

**Patient or population:** women with endometrial hyperplasia  
**Setting:** hospital outpatient clinic  
**Intervention:** metformin  
**Comparison:** megestrol acetate

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Regression of endometrial hyperplasia (with or without atypia) towards normal histology  
Assessed by histological examination  
Follow-up: 3 months | 615 per 1000 (608 to 949) | OR 3.34 (0.97 to 11.57) | 59 (2 RCTs) | ⊕ ⃝⃝⃝ ⚫ ⚫ | VERY LOW<sup>a,b</sup>  
Normal histology is defined as atrophic or proliferative endometrium |
| Recurrence of endometrial hyperplasia | See comment | Not estimable | (0 studies) | - | No data for recurrence of endometrial hyperplasia for this comparison |
| Progression of endometrial hyperplasia to endometrial cancer  
Assessed by histological examination  
Follow-up: 3 months | 0 per 1000 (0 to 0) | Not estimable | 59 (2 RCTs) | ⊕ ⃝⃝⃝ ⚫ ⚫ | VERY LOW<sup>c,d</sup> |
| Hysterectomy rate  
Follow-up: 3 months | 37 per 1000 (2 to 374) | OR 0.91 (0.05 to 15.52) | 61 (2 RCTs) | ⊕ ⃝⃝⃝ ⚫ ⚫ | VERY LOW<sup>c,e</sup> |
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Category</th>
<th>Intervention</th>
<th>comparator</th>
<th>Effect size</th>
<th>No.</th>
<th>GRADE</th>
<th>Evidence quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal uterine bleeding</td>
<td>Assessed by self-report Follow-up: 3 months</td>
<td>48 per 1000 (2 to 437)</td>
<td>44 per 1000</td>
<td>OR 0.91 (0.05 to 15.52)</td>
<td>44 (1 RCT)</td>
<td>⬤⬤⬤⬤</td>
<td>VERY LOW&lt;sup&gt;b,f&lt;/sup&gt;</td>
</tr>
<tr>
<td>Health-related quality of life (HRQL)</td>
<td>See comment</td>
<td></td>
<td>Not estimable</td>
<td>(0 studies)</td>
<td>-</td>
<td>No data for HRQL for this comparison</td>
<td></td>
</tr>
<tr>
<td>Adverse effects during treatment</td>
<td>See comment</td>
<td></td>
<td>Not estimable</td>
<td>(0 studies)</td>
<td>-</td>
<td>No data for adverse effects during treatment for this comparison, with the exception of abnormal uterine bleeding (see above)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> The risk in the intervention group (and its 95% confidence interval) is based on mean risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio; RR: risk ratio.

**GRADE Working Group grades of evidence.**

*High quality:* We are very confident that the true effect lies close to that of the estimate of the effect.

*Moderate quality:* We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

*Low quality:* Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

*Very low quality:* We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>a</sup> Downgraded by two levels for very serious risk of bias: One study was an open-label study; the other did not detail random sequence generation or allocation concealment or blinding; inadequately applied its inclusion criteria to study participants; and was at high risk of attrition bias.

<sup>b</sup> Downgraded by two levels for very serious imprecision: Both studies have very small sample sizes, and confidence intervals are compatible with a large effect in either group or with null effect.

<sup>c</sup> Downgraded by two levels for very serious risk of bias: One study was an open-label study; the other did not detail random sequence generation or allocation concealment or blinding; inadequately applied its inclusion criteria to study participants; and was at high risk of attrition bias. We had concern about inadequate follow-up time to detect this outcome.

<sup>d</sup> Downgraded by two levels for very serious imprecision: Inadequate sample size to capture a relatively uncommon event over too short a period means that confidence intervals could not be generated for this outcome.

<sup>e</sup> Downgraded by two levels for very serious imprecision: Both studies have an inadequate sample size studied over too short a period, and confidence intervals are compatible with a large effect in either group or with null effect.
Downgraded by two levels for very serious risk of bias: The included study was an open-label study that recorded only abnormal uterine bleeding that was self-reported.
BACKGROUND

Description of the condition

Endometrial hyperplasia is a precancerous endometrial lesion that commonly presents with abnormal uterine bleeding. It is thought to be due to unopposed, prolonged exposure of the endometrium to oestrogen and, if managed expectantly, can progress to endometrial carcinoma, although the condition may resolve spontaneously. It is diagnosed histologically and subsequently can be categorised into four subtypes: simple, simple with atypia, complex, and complex with atypia (Kurman 1985). Risk of progression to endometrial carcinoma is dependent on the type of endometrial hyperplasia, and progression rates vary widely across the literature. This discrepancy is likely due, in part, to the fact that many cases of endometrial hyperplasia, especially when atypia is present, are managed pre-emptively with a hysterectomy. However, atypia is thought to be a strong risk factor for progression to adenocarcinoma (Kurman 1985). The latest World Health Organization (WHO) classification for endometrial hyperplasia now differentiates only two categories of endometrial hyperplasia: hyperplasia without atypia and atypical hyperplasia/endometrioid intraepithelial neoplasia (Zaino 2014). Progression rates have been reported as less than 5% for non-atypical hyperplasia but 28% for atypical hyperplasia cumulatively over 20 years. This difference in progression risk has been seen at interval-specific time points of four years, nine years, and 20 years post diagnosis (Lacey 2010). Risk factors for endometrial hyperplasia are, predictably, very similar to those for endometrial carcinoma and include obesity, diabetes mellitus, nulliparity, tamoxifen use, oestrogen therapy, and polycystic ovary syndrome (PCOS) (Torres 2012).

Polycystic ovary syndrome is a metabolically driven gynaecological disorder that is thought to affect 10% of women of childbearing age (Chang 2002). A diagnosis of PCOS must fulfil the widely accepted Rotterdam criteria for two or more of the following in the absence of another cause of chronic anovulation: hyperandrogenism (clinical or biochemical), chronic oligo/amenorrhea, and polycystic ovaries apparent on ultrasound (ESHRE/ASRM 2004). Prevalence of endometrial hyperplasia in women with PCOS varies greatly in the literature - between 5% and 10% (Holm 2012; Rudnicka 2009) - but risk of endometrial carcinoma is well founded, as women with PCOS possess a three-fold increased risk of developing endometrial carcinoma when compared with the non-PCOS population (Haoula 2012).

The aim of endometrial hyperplasia treatment, whether or not PCOS is a comorbidity, is to control abnormal vaginal bleeding while minimising risk of progression to endometrial carcinoma. Historically, endometrial hyperplasia without atypia has been treated medically with oral progestogens (alone or in combination with oestrogen in PCOS) or intrauterine progestogens, inhibiting oestrogen-driven cell growth and inducing withdrawal bleeds (Yang 2011). This treatment provides the benefit of preserving fertility but is associated with side effects - in the short term, headaches, mood changes, and acne or breast tenderness, and over the longer term, risk of a thromboembolic event or breast cancer (BNF 2017). The side effects of these medications has had the effect of potentially hindering compliance, consequently producing a relatively high relapse rate. In one study, 30.3% and 13.7% of women treated with oral progestogens and intrauterine levonorgestrel, respectively, had relapse of their endometrial hyperplasia (Gallos 2013). However, longer-term side effects of progestogens can be mitigated by educating women about the symptoms of thromboembolic events and by ensuring that they attend regular breast cancer screening programmes. For women with atypia and for those who are resistant to progestogens, surgical hysterectomy is the treatment of choice (Shaﬁee 2014).

Description of the intervention

Metformin, a biguanide that acts as an insulin sensitiser, is the oral hypoglycaemic agent most commonly used for treatment of type 2 diabetes mellitus. It acts to inhibit hepatic glucoseogenesis, decreasing liver glucose production and thereby reducing levels of circulating glucose and insulin. Metformin is also prescribed for women with PCOS to induce weight loss and improve menstrual regularity, both as monotherapy and in combination with a progestogen. It is frequently used to treat ovulatory dysfunction in women with PCOS who have shown resistance to treatment with clomiphene. Despite widespread use of metformin in women with PCOS, a systematic review comparing metformin with the oral contraceptive pill found no definitive improvement in clinical or biochemical features (Costello 2007). Metformin has an established side effect profile that includes nausea and vomiting, diarrhoea, abdominal pain, and changes in taste, as well as rarer or less-publicised effects such as lactic acidosis or decreased B₁₂ absorption, possibly leading to anaemia and potentially irreversible neuronal damage if left unmonitored and uncorrected for prolonged periods (de Jager 2010).

How the intervention might work

Hyperinsulinaemia secondary to insulin resistance is thought to exhibit a mitogenic effect, inducing cell division via mitosis - a risk factor for hyperplasia - and, ultimately, carcinoma development. This effect is likely due to its activity at the insulin-like growth factor-1 receptor, promoting proliferation and angiogenesis, which can be demonstrated by the positive correlation between diabetes and breast and gynaecological cancers (Vrachnis 2016). Insulin-mediating effects of metformin, then, show evidence of reducing incidence and improving survival among these malignancies, although the evidence is mixed (Chlebowski 2012; Nevadunsky 2014). The link between insulin resistance and cell proliferation...
offers an intriguing potential therapeutic target for reversing hyperplasia and preventing endometrial carcinoma. Some early trials have corroborated this link, showing effectiveness of metformin in inducing endometrial atrophy in benign endometrial proliferative disorders; one reported atrophy and therefore reversal of endometrial hyperplasia in 96% of women treated with metformin (Tabrizi 2014).

Other proposed mechanisms of the anticancer properties of metformin include its direct effects on cell signalling pathways, including inhibition of the mammalian target of rapamycin (mTOR) and inhibition of mitogen-activated protein kinase (MAPK) and Akt activity. These pathways are involved in cell proliferation and therefore play a key role in both hyperplasia and cancerous lesions in any tissue. As metformin inhibits these pathways, cell proliferation will be hindered, reducing the chance of development of cancerous lesions (Alimova 2009; Ben 2011).

Why it is important to do this review

Medical therapy for endometrial hyperplasia currently involves multiple side effects and continued risk of recurrence. Therefore, a systematic review of a novel, alternative therapy is needed to collate the evidence to date and to guide future clinical trials. Risk of progression from endometrial hyperplasia to carcinoma is significant; up to 28% of women with endometrial hyperplasia with atypia go on to develop carcinoma - the most common fatal gynaecological malignancy (Lacey 2010). This rate is expected to increase globally by up to 100% over the next 20 years (Dowling 2011). The biguanide insulin sensitiser metformin has been linked to reversal of endometrial hyperplasia and, if it can be used in this way, may contribute to decreasing the prevalence of endometrial carcinoma without use of hormonal contraceptives or irreversible infertility following a hysterectomy (Tabrizi 2014). Although publications include in vitro studies reporting reversed endometrial hyperplasia in mice and cell lines, as well as some case reports, results of treatment are relatively ambiguous, and the mode of action, effectiveness, and safety of metformin remain unclear (Erdemoglu 2009; Legro 2007; Rosato 2011; Session 2003; Shen 2008). This review may help to clarify the role of metformin in the treatment of women with this disease.

OBJECTIVES

To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs), both published and unpublished. We also included cross-over trials, but we planned to use in the analysis only data from the first phase of these trials.

Types of participants

We included women with histologically confirmed endometrial hyperplasia of any type.

Types of interventions

We included trials comparing metformin with placebo or no treatment, conventional medical treatment (typically progestogens, e.g. oral or intrauterine), or any other active intervention. We also included trials that provided co-interventions (e.g. metformin plus progesterone vs progesterone), but we planned to analyse results of these studies separately.

Types of outcome measures

Primary outcomes

1. Regression of endometrial hyperplasia histology (with or without atypia) towards normal histology

Secondary outcomes

2. Recurrence of endometrial hyperplasia
3. Progression of endometrial hyperplasia to endometrial cancer
4. Hysterectomy rate
5. Abnormal uterine bleeding
6. Health-related quality of life, as reported in the included studies
7. Adverse effects during treatment, as reported in the included studies

Search methods for identification of studies

We searched for all published and unpublished RCTs of metformin for endometrial hyperplasia without language restriction. Review authors liaised with the Cochrane Gynaecology and Fertility Group Trials Search Co-ordinator and Information Specialist when conducting the search.
**Electronic searches**

In accordance with guidance from the Cochrane Gynaecology and Fertility Group, we created search strategies for the following electronic databases to identify all relevant RCTs. We searched the following databases from date of inception to 10 January 2017.

1. Cochrane Gynaecology and Fertility Specialised Register (ProCite platform; inception to 10 January 2017) (Appendix 1).
2. Cochrane Central Register of Studies Online (CRSO) (Web platform; searched 10 January 2017) (Appendix 2).
3. Ovid MEDLINE (Ovid platform; 1946 to 10 January 2017) (Appendix 3).
4. Ovid Embase (Ovid platform; 1980 to 10 January 2017) (Appendix 4).
5. EBSCO Cumulative Index to Nursing and Allied Health Literature (CINAHL) (Ebsco platform; 1961 to 10 January 2017) (Appendix 5).

We also searched the following trials registers and databases to identify ongoing and unpublished trials.

1. ClinicalTrials.gov (Web platform; searched 10 January 2017) (Appendix 8).
4. Latin American Caribbean Health Sciences Literature (LILACS) (Web platform; searched 10 January 2017) (Appendix 11).

We have presented a list of search strategies in the appendices. For unpublished trials, we emailed the contact person to obtain further information to aid our assessment as to whether they should be included.

**Searching other resources**

We handsearched the bibliographies of all included studies and reviews on this topic. We also handsearched conference abstracts of the European Society of Human Reproduction and Embryology (ESHRE) 2015 and the American Society for Reproductive Medicine (ASRM) 2015, as these were not included in CENTRAL at the time of the search. Previous abstracts from these conferences had been incorporated into the Cochrane Gynaecology and Fertility Specialised Register.

**Data collection and analysis**

**Selection of studies**

We uploaded the titles and abstracts of all studies retrieved by electronic searches to a reference manager programme (Covidence) and removed duplicates. Two review authors (two of NC, TO, JS, HS) independently assessed titles and abstracts to identify studies for potential inclusion in the review. We sought full-text reports for potentially relevant studies. Two review authors (two of NC, TO, JS, HS) then independently assessed each full-text report against the inclusion criteria and documented a justification for exclusion of each study. Review authors resolved disagreements between them regarding trial suitability by discussion or by consultation with a third review author. We screened studies for duplicate publication by comparing study author names and study locations, dates, and durations. When uncertainty about study methods or the possibility of duplicate studies arose, we contacted the authors of relevant papers. We constructed a flow chart (Figure 1) to illustrate selection of studies for inclusion in this review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Moher 2009).
Figure 1. Flow diagram.

232 records identified through database searching

15 records identified through other sources

217 records after duplicates removed

217 records screened

195 records discarded as clearly irrelevant

14 full-text articles excluded:
- 8 Wrong study design
- 3 Wrong participant population
- 3 Wrong outcomes (outcomes not measured histologically)

3 studies ongoing

22 full-text articles assessed for eligibility

Total number of studies included: systematic review
n = 3
Described in 5 reports
Quantitative synthesis
n = 2
Data extraction and management
Two review authors independently extracted data using a data extraction form based on the 'Checklist of items to consider in data collection or data extraction' provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). If, during study selection, we found a study that had been published multiple times, we planned to extract and collate study data into a single file. We treated such studies as a single unit of interest for the review and attributed multiple references to the single file. When necessary, we contacted study authors to request additional data on their methods and/or results.

Assessment of risk of bias in included studies
Two review authors (two of NC, TO, HS, JS) independently assessed each included study for risk of bias using the Cochrane 'Risk of bias' assessment tool, as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We assessed bias according to the following domains.
1. Selection bias (random sequence generation and allocation concealment).
2. Performance bias (blinding of participants and personnel).
3. Detection bias (blinding of outcome assessments).
4. Attrition bias (incomplete outcome data).
5. Reporting bias (selective reporting).
6. Other bias (other sources of bias).

We graded risk of bias as 'low', 'high', or 'unclear' for all domains mentioned above by using the 'Criteria for judging risk of bias' in the 'Risk of bias' assessment tool (Higgins 2011). We resolved disagreements by discussion and, when necessary, by consultation with a third review author. We have provided a justification for each judgement in the 'Risk of bias' table and, when possible, a quote from the study to support this judgement. We considered our risk of bias assessment when interpreting findings of the review, for example, when performing the sensitivity analysis. To minimise bias in selective reporting of trial outcomes, we planned, when possible, to compare published protocols against methods and outcomes described in the final report.

Measures of treatment effect
For survival outcomes (e.g. regression of endometrial hyperplasia, recurrence of endometrial hyperplasia, progression to endometrial carcinoma), we planned to calculate hazard ratios if data were available. Otherwise, we would calculate rates at a set time point, using the Mantel-Haenszel odds ratio (OR) and the numbers of events in control and intervention groups.

For continuous data, we planned to use means, standard deviations, and mean differences (MDs). We planned to treat ordinal data, such as side effect severity scoring systems and health-related quality of life questionnaires, as continuous data for purposes of analysis. If different scales were used to report similar outcomes (e.g. change in endometrial thickness), we planned to calculate the standardised mean difference (SMD). We planned to express the SMD effect as small (0.2 to < 0.5), medium (0.5 to < 0.8), or large (≥ 0.8) (Cohen 1988), and to provide 95% confidence intervals (CIs) for all outcomes.

We planned to report dichotomous and continuous outcomes measured after short-term treatment (up to six months post treatment), medium-term treatment (6 to 12 months post treatment), and long-term treatment (more than 12 months post treatment).

Unit of analysis issues
We performed the primary analysis per woman. If a valid analysis was not possible, we planned to briefly summarise the data but not include them in the meta-analysis. We planned to include in the analysis only first-phase data from cross-over trials.

Dealing with missing data
We analysed the data on an intention-to-treat basis as far as possible and attempted to obtain missing data from the original trialists. When contacting study authors for missing information, we sent a first reminder email 14 days and a second reminder email 21 days after the initial email. When data could not be obtained, we analysed only available data. We have discussed the potential impact of missing data in the Discussion section of the review.

Assessment of heterogeneity
We planned to consider whether clinical and methodological characteristics of included studies were sufficiently similar for meta-analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity using the measure of $I^2$. We considered an $I^2$ greater than 50% to indicate substantial heterogeneity (Higgins 2003; Higgins 2011).

Assessment of reporting biases
Reporting bias is a potential issue for all reviews. We aimed to identify and minimise reporting bias in our analysis by creating a comprehensive search strategy and utilising a multitude of electronic databases, including those that record unpublished work and work prepared in languages other than English. This ensured that we maximised the yield of eligible studies included in the review and were able to identify cases of data duplication.

We planned that if we included 10 or more studies in a single analysis, we would use a funnel plot to explore the possibility of small-
study effects (i.e. the tendency for estimates of the intervention effect to be more beneficial in smaller studies).

Data synthesis
If identified studies were sufficiently similar, we aimed to combine the data in Review Manager software (RevMan 2014) using a fixed-effect model for the following comparisons.
1. Metformin versus placebo or no treatment.
2. Metformin versus progestogens.
3. Metformin versus other active intervention.
4. Metformin plus co-intervention versus co-intervention alone.
We aimed to stratify analyses by dose of metformin (high, moderate, low). We have graphically displayed the results of these meta-analyses, with increasing odds (regardless of whether the outcome is beneficial) demonstrated by a marker right of the centre-line, and decreasing odds by a marker left of the centre-line.

Subgroup analysis and investigation of heterogeneity
When data were available, we aimed to conduct subgroup analyses to obtain separate evidence for the following subgroups.
1. Women with PCOS.
2. Women with atypical endometrial hyperplasia.
If pooled data demonstrate substantial heterogeneity (> 50%), we planned to consider additional subgroup analyses (e.g. by dose or route of metformin) and/or sensitivity analyses. We planned to acknowledge the degree of heterogeneity when interpreting the meta-analysis.

Sensitivity analysis
We aimed to conduct a sensitivity analysis for the primary outcome to determine whether conclusions are robust to our choice of methods with regards to study eligibility and analysis. Through this sensitivity analysis, we planned to explore whether review conclusions would have been different if:
1. all studies with high risk of bias in one or more domains were excluded from the analysis;
2. a random-effects model had been implemented; or
3. the effect estimate had been expressed as risk ratio (RR) rather than OR.

Results of the search
Through the search, we retrieved 217 records; we excluded 195 on the basis of title and abstract review. We sought the full text of the remaining 22 articles and found that eight met our inclusion criteria. We excluded 14 articles. Of the eight full-text articles reviewed, five report findings of three completed studies, and three describe ongoing studies. See study tables Characteristics of included studies, Characteristics of excluded studies, and Characteristics of ongoing studies and the PRISMA flow chart in Figure 1.

Included studies
We included in this review three RCTs, which are described in five articles; three articles describe one study.

Study design and setting
All three included studies were single-centre studies based in hospital outpatient clinics in China or Iran (Shan 2014; Sharifzadeh 2016; Tabrizi 2014).

Participants
In total, investigators randomised 110 women with endometrial hyperplasia across the three RCTs. Critically, histopathological diagnoses reported by each study differed. One included all endometrial hyperplasia, with or without atypia (Tabrizi 2014). One reported only hyperplasia with atypia (Shan 2014). The third described hyperplasia without atypia (Sharifzadeh 2016). Tabrizi included in the randomisation participants with endometrioid endometrial carcinoma and disordered proliferative endometrium,
which we excluded from our analysis in this review (Tabrizi 2014). Shan restricted participants to those under 45 years of age (Shan 2014). The other two studies applied no age restriction.

**Interventions**

Two studies compared metformin against megestrol acetate (Sharifzadeh 2016; Tabrizi 2014). The other included study examined metformin and megestrol acetate dual therapy against megestrol acetate monotherapy (Shan 2014).

**Outcomes**

Two studies measured outcomes at 12 weeks (Shan 2014; Sharifzadeh 2016). One measured outcomes at three months (Tabrizi 2014). Thus for all eligible studies, analysis could be performed only on "short-term treatment" outcomes. All studies reported on the review's primary outcome - regression of endometrial hyperplasia towards normal histology. Additionally, study authors reported on progression of endometrial hyperplasia to endometrial cancer, when it occurred.

**Excluded studies**

We excluded 14 full-text reports for the following reasons.
1. Eight were not RCTs.
2. Three did not include women with endometrial hyperplasia.
3. Three did not measure outcomes histologically.

**Ongoing studies**

We identified three ongoing studies, two of which are due to be completed in 2017 (we contacted study authors throughout the review process to request preliminary results) and one in 2019.

**Risk of bias in included studies**

We have shown risk of bias as judged by review authors for all domains in Figure 2 and have summarised this information in Figure 3.

---

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**

<table>
<thead>
<tr>
<th>Risk of Bias Category</th>
<th>Percentage Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk: 75%</td>
</tr>
<tr>
<td></td>
<td>Unclear risk: 25%</td>
</tr>
</tbody>
</table>

Legend:
- Low risk of bias
- Unclear risk of bias
- High risk of bias
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
Allocation

Sequence generation
We judged that one study was at low risk of bias related to sequence generation, as researchers used a computer to generate a randomised table (Shan 2014). We determined that the remaining two studies were at unclear risk of this bias, as trialists did not describe the method used (Sharifzadeh 2016; Tabrizi 2014).

Allocation concealment
We thought that one study was at low risk of allocation concealment bias, as investigators used sealed envelopes (Sharifzadeh 2016). We determined that two studies were at unclear risk of bias, as study authors did not describe the method used (Shan 2014; Tabrizi 2014).

Blinding
We considered under our primary outcome that lack of blinding may influence symptom reporting by both investigators and patients but not histological results. Therefore, two studies in which neither patients nor investigators were blinded had high risk of bias for this domain (Shan 2014; Sharifzadeh 2016). One study did report blinding of data analysers (Shan 2014). The remaining study described no blinding process, and we therefore judged this trial to be at unclear risk of bias for this domain (Tabrizi 2014).

Incomplete outcome data
Two studies were at low risk related to attrition bias. One of these studies reported that no participants of 43 were lost from the study (Tabrizi 2014). The other reported that only three participants of 45 were lost: One was lost to follow-up and two discontinued the intervention (Sharifzadeh 2016). We judged the remaining study to be at high risk of bias in this domain (Shan 2014; Sharifzadeh 2016). We performed no subgroup analysis (Tabrizi 2014).

Selective reporting
We judged all three studies to be at unclear risk of reporting bias owing to lack of publication of protocols before studies were published (Shan 2014; Sharifzadeh 2016; Tabrizi 2014). Two studies excluded participants “lost to follow-up” from any analysis, but it remains unclear whether available case analysis had been planned within their protocols (Shan 2014; Sharifzadeh 2016). All three studies reported all outcomes appropriately.

Other potential sources of bias
We judged that one study had potential sampling bias, as participants were not matched between intervention and control groups by histology, age, features of metabolic syndrome, or PCOS diagnosis, and therefore investigators did not control for these known risk factors for development of endometrial hyperplasia (Tabrizi 2014). This study also had potential exclusion bias as, although diagnosis of diabetes was an exclusion criterion, some pre-intervention blood glucose values appear to show some undiagnosed cases of diabetes but were still included, showing inconsistent exclusion of diabetic patients - again a known effector of endometrial histology.
We identified no potential sources of within-study bias in the remaining two studies.

Effects of interventions
See: Summary of findings for the main comparison Metformin compared with megestrol acetate for endometrial hyperplasia; Summary of findings 2 Metformin plus megestrol acetate compared with megestrol acetate for endometrial hyperplasia

1. Metformin versus megestrol acetate
We included two studies in this comparison.

Primary outcome

1.1 Regression of endometrial hyperplasia histology (with or without atypia) towards normal histology
Evidence was insufficient to show whether there was any difference in rates of regression of endometrial hyperplasia histology towards normal histology when metformin was compared with megestrol acetate (odds ratio (OR) 3.34, 95% confidence interval (CI) 0.97 to 11.57, two RCTs, n = 59, I² = 0%, very low-quality evidence; Analysis 1.1). Although one study reported the presence or absence of atypia, data were insufficient to track these participants from initial to final histological results; therefore, we performed no subgroup analysis (Tabrizi 2014).

Secondary outcomes

1.2 Progression of endometrial hyperplasia to endometrial cancer
Two studies provided data for this outcome (n = 59) but reported no events in either arm (Analysis 1.2).
1.3 Hysterectomy rate
It is uncertain whether metformin and megestrol acetate are different in terms of hysterectomy rates (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 61, very low-quality evidence; Analysis 1.3).

1.4 Abnormal uterine bleeding
It is unresolved whether metformin and megestrol acetate showed a difference in rates of abnormal uterine bleeding (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 44, very low-quality evidence; Analysis 1.4). The only study contributing data to this analysis reported only two events.

Other secondary outcomes
Study authors provided no data on recurrence of endometrial hyperplasia, health-related quality of life, or adverse events, with the exception of abnormal uterine bleeding, as described above.

2. Metformin plus megestrol acetate versus megestrol acetate alone
We included only one study in this comparison.

Primary outcome

2.1 Regression of endometrial hyperplasia histology (with or without atypia) towards normal histology
Whether metformin plus megestrol acetate and megestrol acetate alone are different in terms of rates of regression of endometrial hyperplasia histology towards normal histology remains uncertain (OR 9.00, 95% CI 0.94 to 86.52, one RCT, n = 16, very low-quality evidence; Analysis 2.1). The single study included in this analysis recorded only eight events.

Secondary outcomes

2.2 Recurrence of endometrial hyperplasia
Whether metformin plus megestrol acetate and megestrol acetate alone are different in terms of rates of recurrence of endometrial hyperplasia among women who achieve regression remains unresolved (OR not estimable, 95% CI not estimable, one RCT, n = 8, very low-quality evidence; Analysis 2.2). The single study included in this analysis recorded no events.

2.3 Progression of endometrial hyperplasia to endometrial cancer
Whether metformin plus megestrol acetate and megestrol acetate alone are different in terms of rates of progression of endometrial hyperplasia to endometrial cancer remains uncertain (OR not estimable, 95% CI not estimable, one RCT, n = 16, I² = not applicable, very low-quality evidence; Analysis 2.3). The single study included in this analysis recorded no events.

2.4 Hysterectomy rate
Whether metformin plus megestrol acetate and megestrol acetate alone are different in terms of hysterectomy rates in women with endometrial hyperplasia remains unresolved (OR 0.29, 95% CI 0.01 to 8.37, one RCT, n = 16, I² = not applicable, very low-quality evidence; Analysis 2.4). The single study included in this analysis recorded only two events: one in the intervention arm and one in the study control arm.

2.5 Adverse effects during treatment
Three of eight women (37.5%) in the metformin plus megestrol acetate study arm reported nausea; however, this was resolved without further treatment (Analysis 2.5). Investigators recorded additional adverse effects during the follow-up period, including thrombosis, lactic acidosis, abnormal liver and renal function, and other toxicities and complaints, but whether these were merely inquired about or occurred within participant populations remains unclear.

Other secondary outcomes
Study authors provided no data on abnormal uterine bleeding or health-related quality of life.

Other analyses
Data were insufficient for performance of subgroup analyses. Sensitivity analysis by risk of bias was not appropriate because we judged all included studies to have high risk of bias. Sensitivity analyses by effect estimate and choice of statistical model did not substantially change the main findings of this review.
### ADDITIONAL SUMMARY OF FINDINGS

**Metformin plus megestrol acetate compared with megestrol acetate for endometrial hyperplasia**

**Patient or population:** women with endometrial hyperplasia  
**Setting:** hospital outpatient clinic  
**Intervention:** metformin plus megestrol acetate  
**Comparison:** megestrol acetate

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| **Regression of endometrial hyperplasia (with or without atypia) towards normal histology**  
Assessed by histological examination  
Follow-up: 3 months                                                        | Risk with megestrol acetate | 250 per 1000 (239 to 966) | OR 9.00 (0.94 to 86.52)          | 16 (1 RCT)                      | ⊕⊕⊕⊕ VERY LOWₘₜₜₜₜ.₁,₂  
Normal histology is defined as proliferative or secretory endometrium |
| Risk with metformin plus megestrol acetate                                | 750 per 1000 |  | | | |
| **Recurrence of endometrial hyperplasia**  
Follow-up: median 10.5 months                                              | Risk with megestrol acetate | 0 per 1000 (0 to 0) | Not estimable                    | 8 (1 RCT)                       | ⊕⊕⊕⊕ VERY LOWₘₜₜₜₜ.₁,₂  
Measured in the subset of women who achieved regression |
| Risk with metformin plus megestrol acetate                                | 0 per 1000 |  | | | |
| **Progression of endometrial hyperplasia to endometrial cancer**  
Follow-up: median 10 months                                               | Risk with megestrol acetate | 0 per 1000 (0 to 0) | Not estimable                    | 16 (1 RCT)                      | ⊕⊕⊕⊕ VERY LOWₘₜₜₜₜ.₁,₂ |
| Risk with metformin plus megestrol acetate                                | 0 per 1000 |  | | | |
| **Hysterectomy rate**                                                     | Risk with megestrol acetate | 125 per 1000 (1 to 545) | OR 0.29 (0.01 to 8.37)           | 16 (1 RCT)                      | ⊕⊕⊕⊕ VERY LOWₘₜₜₜₜ.₁,₂ |
| Risk with metformin plus megestrol acetate                                | 40 per 1000 |  | | | |
Abnormal uterine bleeding

See comment

Not estimable (0 studies) -

No data for abnormal uterine bleeding for this comparison

Health-related quality of life (HRQL)

See comment

Not estimable (0 studies) -

No data for HRQL for this comparison

Adverse effects during treatment

Assessed self-report

3/8 (37.5%) of participants who took metformin had nausea that settled without further treatment. Adverse effects, including "thrombosis, lactic acidosis, abnormal liver and renal function, and other toxicities or complaints" were recorded

- (1 RCT)

⊕⊕⊕⊝

VERY LOW

* The risk in the intervention group (and its 95% confidence interval) is based on mean risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

a Downgraded two levels for very serious risk of bias: The included study provided inadequate detail regarding study design, which was insufficiently clarified when study authors were approached. The random sequence generation was altered, and the allocation concealment was unclear. This was an open-label study with attrition of 6 of the original 22 randomised participants during the period of the study who were not evaluated by an intention-to-treat analysis. For the outcome of regression, only a subset of women were included in the analysis.

b Downgraded by two levels for very serious imprecision: Very low event rate and/or confidence intervals are compatible with a large effect in one or both groups, or with null effect.

c Downgraded by two levels for very serious imprecision: Sample size was tiny, follow-up was short, and no events were reported.
DISCUSSION

Summary of main results
Two of the three studies included in this review compared metformin against megestrol acetate, and one study compared metformin and megestrol acetate dual therapy against megestrol acetate monotherapy. Trial results provided no evidence to support or refute short-term use of metformin either alone or in combination with megestrol acetate for treatment of endometrial hyperplasia versus megestrol acetate alone. Whether these treatments are different in terms of rates of hysterectomy, abnormal uterine bleeding, alteration in endometrial histology, or rates of progression to endometrial cancer remains uncertain. The quality of the evidence is very low.

Overall completeness and applicability of evidence
We undertook a comprehensive search of a range of databases and trials registries with no language restrictions to identify published, unpublished, and ongoing studies. Thus we are confident that we have identified all potentially relevant randomised controlled trials (RCTs). However, we identified for inclusion in this review only three studies conducted in only two countries; all had small sample sizes, and consequently overall applicability remains unclear. Completeness of evidence was limited by lack of subgroup data (whether effects were the same in individuals both with and without atypia) and by the relatively short-term follow-up explored (12 weeks or 3 months in all three studies).

Quality of the evidence
Using GRADE, review authors determined that the evidence was of very low quality both for the main comparison of metformin versus megestrol acetate and for the additional comparison of metformin plus megestrol acetate versus megestrol acetate alone. For both comparisons, we downgraded the quality of evidence owing to very serious risk of bias (associated with poor reporting, attrition, and limitations in study design) and imprecision as major factors. All studies had very small sample sizes, especially when assessing relatively rare events such as progression of endometrial hyperplasia to endometrial cancer. Confidence intervals were compatible with a large effect in one or both groups, or with a null effect.

Potential biases in the review process
We conducted this review according to guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Two review authors independently performed each step of the review process, thus reducing potential bias when subjective decisions were required. When the two review authors disagreed, we sought the opinions of a third review author. Furthermore, this review has undergone peer review; thus we are confident that the findings reported here are a true representation of current evidence pertaining to this question. Investigators excluded from the study’s final analysis 6 of the 22 randomised participants (Shan 2014). Study authors provided no details of participants excluded owing to incomplete data, nor did they provide data previously collected for these participants. Study authors provided no data on participants who dropped out. This was reflected in our rating of attrition bias for the study. We note that standard therapy doses for metformin and megestrol acetate and megestrol acetate in combination with metformin differed, and we recognise the impact this may have had on the therapeutic response. However, we did not directly compare in this review studies in which these doses differed but included them in two separate comparisons. We made the decision to include one study even though the authors of this study performed only subgroup analysis (Tabrizi 2014). We made this decision because the subgroup analysis was relevant to the study, and further evidence available in the literature was limited.

Agreements and disagreements with other studies or reviews
To our knowledge, no systematic review has compared the effects of metformin versus megestrol acetate nor the effects of metformin plus megestrol acetate versus megestrol acetate alone.

AUTHORS’ CONCLUSIONS

Implications for practice
Review authors found insufficient evidence to support or refute the use of metformin given alone or in combination with standard therapy, specifically megestrol acetate, for treatment of women with endometrial hyperplasia.

Implications for research
Well-designed randomised controlled clinical trials are required to investigate the effectiveness and safety of metformin for treating women with endometrial hyperplasia in comparison with other interventions, including oral or intrauterine progestogens. These trials should provide long-term follow-up of women with endometrial hyperplasia (both with and without atypia) in all arms of the trial, including assessment of progression to endometrial carcinoma and assessment of quality of life.
ACKNOWLEDGEMENTS

We would like to thank the Cochrane Gynaecology and Fertility Group (formerly the Menstrual Disorders and Subfertility Group) in Auckland for help and support provided, especially Marian Showell for assistance with the search protocols, and Helen Nagels as the Managing Editor. We thank Jane Marjoribanks for invaluable advice on writing up this review.

REFERENCES

References to studies included in this review

Shan 2014 [published and unpublished data]


Sharifzadeh 2016 [published data only]

Tabrizi 2014 [published and unpublished data]

References to studies excluded from this review

Campagnoli 2013 [published data only]

IRCT201412085563N6, 2015 [published data only]

Legro 2007 [published data only]

Mitsuhashi 2014 [published data only]

Mitsuhashi 2016 [published data only]

NCT01685762 [published and unpublished data]

NCT02035787, 2014 [published and unpublished data]
NCT02035787. UNC Lineberger Comprehensive Cancer Center. Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. clinicaltrials.gov 2014.

Perez-Lopez 2014 [published data only]

Randall 2014 [published data only]

Shen 2008 [published data only]
References to ongoing studies

IRCT201410275283N11 [published data only (unpublished sought but not used)]

NCT01686126 [published data only (unpublished sought but not used)]

NCT01968317 [published data only (unpublished sought but not used)]

Additional references


BNF 2017

Chang 2002

Chlebowski 2012

Cohen 1988

Costello 2007

Covidence [Computer program]

de Jager 2010

Dowling 2011

Erdemoglu 2009

ESHRE/ASRM 2004
Gallos 2013

GRADEpro GDT 2015 [Computer program]

Haoula 2012

Higgins 2003

Higgins 2011

Holm 2012

Kurman 1985

Lacey 2010

Moher 2009

Nevadunsky 2014

RevMan 2014 [Computer program]

Rosato 2011

Rudnicka 2009

Session 2003

Shafiee 2014

Torres 2012

Vrachnis 2016

Yang 2011

Zaino 2014

References to other published versions of this review
Clement 2016
Clement NS, Oliver TRW, Shiwani H, Sanner JRF, Mulvaney CA, Atiomo W. Metformin for endometrial
* Indicates the major publication for the study
### Characteristics of included studies  
*ordered by study ID*

#### Shan 2014

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Methods**     | Randomised controlled trial  
22 randomised participants, 16 included in the analysis  
Timing: August 2012 to January 2013  
Setting: hospital outpatient clinic, in China |
| **Participants** | Women given a pathological diagnosis of endometrial atypical hyperplasia  
Aged 45 years or less  
Participants expressed a desire to preserve fertility |
| **Interventions** | Metformin plus megestrol acetate (n = 8): received 500 mg of oral metformin 3 times a day and 160 mg of oral megestrol acetate daily  
Megestrol acetate (n = 8): received 160 mg of oral megestrol acetate daily  
Both groups: 12 weeks of therapy |
| **Outcomes**    | Regression of endometrial hyperplasia histology (with or without atypia) towards normal histology; Recurrence of endometrial hyperplasia among women who had regression; Progression of endometrial hyperplasia to endometrial cancer; Hysterectomy rate; Adverse effects during treatment, as reported in the included studies |
| **Notes**       | Of 6 not included in the analysis, 3 participants were lost to follow-up and 3 had incomplete data, leaving 8 participants in each group |

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Communication with authors: “Using computer, we got a randomized table with a total sample of 16. Actually, we used function &quot;RAND&quot; in excel to form the table and changed these randomized numbers to 0 or 1. When a subject was enrolled, she would get a number. 0 means MA only and 1 means MA + metformin.”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Communication with authors: “Using computer, we got a randomized table with a total sample of 16. Actually, we used function &quot;RAND&quot; in excel to form the table and changed these randomized numbers to 0 or 1. When a subject was enrolled, she would get a number. 0 means MA only and 1 means MA + metformin.”</td>
</tr>
</tbody>
</table>
### Shan 2014  (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel</td>
<td>Low risk</td>
<td>Communication with authors: “This study was an open label study. However, when analyzing the data, the analyzer kept unknown of the certain meaning of number 0 or 1. And only investigator or sponsor had the right of access to personal data of subjects.”</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Communication with authors: “This study was an open label study. However, when analyzing the data, the analyzer kept unknown of the certain meaning of number 0 or 1.”</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Of the 30 participants, 16 completed 12 weeks of therapy. 8 women chose to undergo an operation and were excluded before randomisation, 3 were lost during follow-up, and 3 had incomplete data and were excluded from the end analysis (no blood test results available). It is unclear why the absence of blood test data meant that participants were omitted from histological assessment</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>No protocol was published before publication of the study. Outcomes have been appropriately reported. 3 participants died following completion of the study and were not included in the analysis, but it is unclear whether available case analysis had been planned</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No suggestion of other sources of bias</td>
</tr>
</tbody>
</table>

### Sharifzadeh 2016

<table>
<thead>
<tr>
<th>Method</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td></td>
<td>45 randomised participants, 42 included in the analysis</td>
</tr>
<tr>
<td></td>
<td>Timing: February to May 2016</td>
</tr>
<tr>
<td></td>
<td>Setting: hospital outpatient clinic, in Iran</td>
</tr>
<tr>
<td>Participants</td>
<td>Women with histopathologically confirmed simple endometrial hyperplasia without atypia</td>
</tr>
<tr>
<td>Interventions</td>
<td>Metformin (n = 22): received 500 mg oral metformin twice daily for 4 weeks, then 500 mg 3 times a day for a further 8 weeks</td>
</tr>
<tr>
<td></td>
<td>Megestrol acetate (n = 20): 40 mg oral megestrol acetate daily for 12 weeks</td>
</tr>
</tbody>
</table>
Both groups: 12 weeks of therapy

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Regression of endometrial hyperplasia histology (with or without atypia) towards normal histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notes</td>
<td>1 participant were lost to follow-up and 2 discontinued treatment, both in the megestrol acetate arm</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Communication with authors: “Randomization was performed using sealed, sequentially distributed envelopes to which the letters A and B had been allocated: the letter A to the metformin group and the letter B to the megestrol group. The patients chose one of the envelopes which were opened by the investigator’s colleague and, based on the letters, the groups of patients were determined.”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Communication with authors: “Randomization was performed using sealed, sequentially distributed envelopes to which the letters A and B had been allocated: the letter A to the metformin group and the letter B to the megestrol group. The patients chose one of the envelopes which were opened by the investigator’s colleague and, based on the letters, the groups of patients were determined.”</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Communication from trial authors: “The investigators and patients were not blind to interventions.”</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Communication from trial authors: “The investigators and patients were not blind to interventions.”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>1 participant was lost to follow-up and 2 discontinued intervention</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Protocol was not published. 1 participant was lost to follow-up and 2 discontinued intervention. These participants were excluded from the analysis, but it is unclear</td>
</tr>
</tbody>
</table>
### Tabrizi 2014

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised controlled trial (subgroup analysis for the purposes of this review; see below)</td>
</tr>
<tr>
<td>43 randomised participants, all 43 analysed by study authors</td>
</tr>
<tr>
<td>Review authors excluded 26 participants as they had a histological diagnosis of “Disordered proliferative endometrium” or “Endometrioid endometrial carcinoma” at baseline, leaving 17 participants for analysis</td>
</tr>
<tr>
<td>Timing: May to August 2013</td>
</tr>
<tr>
<td>Setting: hospital outpatient clinic, in Iran</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study authors state that they included participants with abnormal uterine bleeding and a histological diagnosis of disordered endometrial proliferation or simple hyperplasia; however, the randomised participant cohort also includes individuals with endometrial carcinoma and complex hyperplasia, with and without atypia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin (n = 11): received oral metformin 500 mg daily in the first to fourth week, then 500 mg twice daily from the fourth week onwards</td>
</tr>
<tr>
<td>Megestrol acetate (n = 6): received oral megestrol acetate 40 mg daily</td>
</tr>
<tr>
<td>Both groups: 3 months of therapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regression of endometrial hyperplasia histology (with or without atypia) towards normal histology; Progression of endometrial hyperplasia to endometrial cancer</td>
</tr>
</tbody>
</table>

### Notes

We contacted study authors to request more information on random sequence generation, allocation concealment, and blinding processes for participants, personnel, and outcomes. They provided no relevant information

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information within method regarding assessing risk of bias, even after study authors were contacted</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information within method regarding assessing risk of bias, even after study authors were contacted</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Insufficient information within method regarding assessing risk of bias, even after study authors were contacted</td>
</tr>
</tbody>
</table>
Blinding of outcome assessment (detection bias)
All outcomes | Unclear risk | Insufficient information within method regarding assessing risk of bias, even after study authors were contacted

Incomplete outcome data (attrition bias)
All outcomes | High risk | Outcome data incomplete for participants included in this review relative to the whole cohort randomised

Selective reporting (reporting bias)
Unclear risk | No protocol was published before the study report was published, so it is difficult to establish whether selective outcome reporting occurred

No adverse effects were reported.

Other bias | High risk | 1. Potential sampling bias: intervention and control groups not matched by histology, age, features of metabolic syndrome, or PCOS. Study reports inclusion criteria to be histology of DPE or SH only, yet participants with CH and EEC are included in the metformin pretreatment group
2. Exclusion bias as diabetic patients were excluded, yet if pre-intervention blood glucose values are assumed to be fasting, it is likely that some individuals with undiagnosed diabetes were included. Inconsistent exclusion of diabetic patients may have occurred

CH: Complex Hyperplasia
DPE: Disordered Proliferative Endometrium
EEC: Endometrioid Endometrial Cancer
MA: Megestrol Acetate
PCOS: Polycystic Ovary Syndrome
SH: Simple Hyperplasia

**Characteristics of excluded studies**  
*ordered by study ID*

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campagnoli 2013</td>
<td>Wrong study design (review of role of metformin in endometrial pathology; not original study)</td>
</tr>
<tr>
<td>IRCT201412085563N6, 2015</td>
<td>Wrong study design (single-arm study; not blinded; no placebo or control)</td>
</tr>
</tbody>
</table>
(Continued)

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legro 2007</td>
<td>Wrong patient population (patients with PCOS, not EH)</td>
</tr>
<tr>
<td>Mitsuhashi 2014</td>
<td>Wrong patient population (patients with preoperative endometrial cancer, not EH)</td>
</tr>
<tr>
<td>Mitsuhashi 2016</td>
<td>Wrong study design (patients with endometrial cancer used in second study arm instead of control patients)</td>
</tr>
<tr>
<td>NCT01685762</td>
<td>Wrong study design (single-arm study)</td>
</tr>
<tr>
<td>NCT02035787, 2014</td>
<td>Wrong study design (single-arm, open-label study)</td>
</tr>
<tr>
<td>Perez-Lopez 2014</td>
<td>Wrong patient population (patients with endometrial cancer instead of patients with EH)</td>
</tr>
<tr>
<td>Randall 2014</td>
<td>Wrong study design (review of existing studies; no original data)</td>
</tr>
<tr>
<td>Shen 2008</td>
<td>Wrong study design (single-arm, non-blinded study)</td>
</tr>
<tr>
<td>Sivalingam 2015</td>
<td>Wrong outcomes (outcomes not measured histologically)</td>
</tr>
<tr>
<td>Sivalingam 2016</td>
<td>Wrong outcomes (outcomes not measured histologically)</td>
</tr>
<tr>
<td>Sivalingham 2015b</td>
<td>Wrong outcomes (outcomes not measured histologically)</td>
</tr>
<tr>
<td>Zhou 2015</td>
<td>Wrong study design (no control arm)</td>
</tr>
</tbody>
</table>

EH: Endometrial Hyperplasia  
PCOS: Polycystic Ovary Syndrome

**Characteristics of ongoing studies**  
*ordered by study ID*

**IRCT201410275283N11**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison of metformin-megestrol acetate combination and megestrol acetate alone on endometrial histology in patients with disordered proliferative or hyperplastic endometrium</td>
<td>Comparison of metformin-megestrol acetate combination and megestrol acetate alone on endometrial histology in patients with disordered proliferative or hyperplastic endometrium</td>
</tr>
<tr>
<td>Methods</td>
<td>Randomised clinical trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Female patients with abnormal uterine bleeding and having disordered proliferative or hyperplastic endometrium with or without atypia</td>
</tr>
<tr>
<td>Interventions</td>
<td>Metformin 500 mg twice a day with megestrol 40 mg daily vs megestrol acetate 40 mg daily for 3 months</td>
</tr>
</tbody>
</table>
| Outcomes                                                                          | Primary outcome  
Endometrial pathology                                                  |
<table>
<thead>
<tr>
<th><strong>IRCT201410275283N11</strong> <em>(Continued)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>

**NCT01686126**

<table>
<thead>
<tr>
<th><strong>Trial name or title</strong></th>
<th>Improving the treatment for women with early stage cancer of the uterus (feMMe)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised parallel-group open-label trial</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Participants</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Females with a BMI &gt; 30 kg/m² wishing to retain fertility, or females at high risk of surgical complications owing to co-morbidities or obesity</td>
</tr>
<tr>
<td>2. Over 18 years of age at time of randomisation</td>
</tr>
<tr>
<td>3. Histologically confirmed complex endometrial hyperplasia with atypia or grade 1 endometrioid endometrial adenocarcinoma on a curette or endometrial biopsy</td>
</tr>
<tr>
<td>4. CT or MRI scan of pelvis, abdomen, and chest (or chest x-ray) suggesting absence of extrauterine disease</td>
</tr>
<tr>
<td>5. Myometrial invasion on MRI not greater than 50% for women with histologically confirmed endometrial cancer only (for women who are unable to fit into an MRI machine, inclusion in trial is decided at investigator’s discretion)</td>
</tr>
<tr>
<td>6. No lymph vascular invasion on curette or pipelle, if able to be assessed on sample</td>
</tr>
<tr>
<td>7. Serum CA125 ≤ 30 U/mL</td>
</tr>
<tr>
<td>8. No hypersensitivity or contraindications for Mirena</td>
</tr>
<tr>
<td>9. Ability to comply with endometrial biopsies at specified intervals</td>
</tr>
<tr>
<td>10. Negative serum or urine pregnancy test in premenopausal women and women &lt; 2 years after onset of menopause</td>
</tr>
<tr>
<td>11. Creatinine &lt; 150 µmol/L (1.7 mg/dL) to be randomised into Mirena + Metformin arm (can still be eligible to be randomised to Mirena only or Mirena + Weight loss (see Section 5.4, Other Eligibility Criteria Considerations)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Interventions</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Levonorgestrel (Mirena) 52 mg Intrauterine drug delivery system + Metformin</td>
</tr>
<tr>
<td>2. Levonorgestrel (Mirena) 52 mg Intrauterine drug delivery system</td>
</tr>
<tr>
<td>3. Levonorgestrel (Mirena) 52 mg Intrauterine drug delivery system + Weight loss</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Outcomes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
</tr>
<tr>
<td>1. Predicted response to treatment</td>
</tr>
<tr>
<td>2. Predicted response to treatment through blood and tissue molecular biomarkers</td>
</tr>
<tr>
<td>3. Increased molecular understanding of the biological pathogenesis of “early” EAC</td>
</tr>
</tbody>
</table>

| **Starting date** | October 2012 |
| **Contact information** | Vanessa L Taylor; vanessa.taylor3@health.qld.gov.au |
**NCT01686126 (Continued)**

<table>
<thead>
<tr>
<th>Notes</th>
</tr>
</thead>
</table>
| Study author correspondence: expected completion July 2019  
[https://clinicaltrials.gov/ct2/show/NCT01686126](https://clinicaltrials.gov/ct2/show/NCT01686126) |

---

**NCT01968317**

<table>
<thead>
<tr>
<th>Trial name or title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megestrol acetate plus metformin to megestrol acetate in patients with endometrial atypical hyperplasia or early stage endometrial adenocarcinoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized parallel-group open-label trial</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
</table>
| 1. 18- to 45-year-old females  
2. Primarily with confirmed diagnosis of endometrial atypical hyperplasia based upon D&C or hysteroscopy OR primarily with confirmed diagnosis of endometrial adenocarcinoma (G1, low tumour grade) based upon D&C or hysteroscopy, and 3 MRI parameters showing no myometrial invasion, extension beyond corpus, or enlarged lymph nodes  
3. Desire to retain reproductive function or uterus  
4. Need to be able to undergo correlative treatment and follow-up |

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megestrol acetate + Metformin or megestrol acetate alone</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
</table>
| Primary outcome  
Pathological response rate  
Secondary outcomes  
1. Toxicity evaluation  
2. Rate of relapse  
3. Rate of pregnancy |

<table>
<thead>
<tr>
<th>Starting date</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2013</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xiaojun Chen; <a href="mailto:cxjlhjj@163.com">cxjlhjj@163.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
</tr>
</thead>
</table>
| Study author correspondence: trial recruited over 90 patients; expected completion at end of 2017  
[https://clinicaltrials.gov/ct2/show/NCT01968317](https://clinicaltrials.gov/ct2/show/NCT01968317) |

---

BMI: Body Mass Index  
CT: Computed Tomography  
D&C: Dilation & Curettage  
EAC: Esophageal Adenocarcinoma  
MRI: Magnetic Resonance Imaging
## DATA AND ANALYSES

### Comparison 1. Metformin versus megestrol acetate

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as atrophic or proliferative endometrium)</td>
<td>2</td>
<td>59</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>3.34 [0.97, 11.57]</td>
</tr>
<tr>
<td>2 Progression of endometrial hyperplasia to endometrial cancer</td>
<td>2</td>
<td>59</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>3 Hysterectomy rate</td>
<td>2</td>
<td>61</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.91 [0.05, 15.52]</td>
</tr>
<tr>
<td>4 Abnormal uterine bleeding</td>
<td>1</td>
<td>44</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.91 [0.05, 15.52]</td>
</tr>
</tbody>
</table>

### Comparison 2. Metformin plus megestrol acetate versus megestrol acetate

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as proliferative/secretory endometrium)</td>
<td>1</td>
<td>16</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>9.0 [0.94, 86.52]</td>
</tr>
<tr>
<td>2 Recurrence of endometrial hyperplasia</td>
<td>1</td>
<td>8</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>3 Progression of endometrial hyperplasia to endometrial cancer</td>
<td>1</td>
<td>16</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>4 Hysterectomy rate</td>
<td>1</td>
<td>16</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.29 [0.01, 8.37]</td>
</tr>
<tr>
<td>5 Adverse effects during treatment</td>
<td>1</td>
<td>16</td>
<td>Other data</td>
<td>No numeric data</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1 Metformin versus megestrol acetate, Outcome 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as atrophic or proliferative endometrium).

**Review:** Metformin for endometrial hyperplasia

**Comparison:** 1 Metformin versus megestrol acetate

**Outcome:** 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as atrophic or proliferative endometrium)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin n/N</th>
<th>Megestrol acetate n/N</th>
<th>Odds Ratio M-H,Fixed(95% CI)</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed(95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharifzadeh 2016</td>
<td>18/22</td>
<td>12/20</td>
<td>82.9 % 3.00 [0.74, 12.23]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tabrizi 2014</td>
<td>10/11</td>
<td>4/6</td>
<td>17.1 % 5.00 [0.35, 71.90]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>33</strong></td>
<td><strong>26</strong></td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>3.34 [0.97, 11.57]</strong></td>
</tr>
</tbody>
</table>

Total events: 28 (Metformin), 16 (Megestrol acetate)
Heterogeneity: Ch² = 0.11, df = 1 (P = 0.74); I² = 0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable

### Analysis 1.2. Comparison 1 Metformin versus megestrol acetate, Outcome 2 Progression of endometrial hyperplasia to endometrial cancer.

**Review:** Metformin for endometrial hyperplasia

**Comparison:** 1 Metformin versus megestrol acetate

**Outcome:** 2 Progression of endometrial hyperplasia to endometrial cancer

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin n/N</th>
<th>Megestrol acetate n/N</th>
<th>Odds Ratio M-H,Fixed(95% CI)</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed(95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharifzadeh 2016</td>
<td>0/22</td>
<td>0/20</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tabrizi 2014</td>
<td>0/11</td>
<td>0/6</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>33</strong></td>
<td><strong>26</strong></td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 0 (Metformin), 0 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable

---

*Metformin for endometrial hyperplasia (Review)*

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 1.3. Comparison 1 Metformin versus megestrol acetate, Outcome 3 Hysterectomy rate.

**Review:** Metformin for endometrial hyperplasia

**Comparison:** 1 Metformin versus megestrol acetate

**Outcome:** 3 Hysterectomy rate

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin</th>
<th>Megestrol acetate</th>
<th>Odds Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharifzadeh 2016</td>
<td>1/23</td>
<td>1/21</td>
<td></td>
<td>100.0%</td>
<td>0.91 [0.05, 15.52]</td>
</tr>
<tr>
<td>Tabrizi 2014</td>
<td>0/11</td>
<td>0/6</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>34</strong></td>
<td><strong>27</strong></td>
<td><strong>100.0%</strong></td>
<td>0.91 [0.05, 15.52]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 1 (Metformin), 1 (Megestrol acetate)

Heterogeneity: not applicable

Test for overall effect: Z = 0.07 (P = 0.95)

Test for subgroup differences: Not applicable
### Analysis 1.4. Comparison 1 Metformin versus megestrol acetate, Outcome 4 Abnormal uterine bleeding.

Review: Metformin for endometrial hyperplasia  
Comparison: 1 Metformin versus megestrol acetate  
Outcome: 4 Abnormal uterine bleeding

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin</th>
<th>Megestrol acetate</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharifzadeh 2016</td>
<td>1/23</td>
<td>1/21</td>
<td>0.91 [ 0.05, 15.52 ]</td>
<td>100.0 %</td>
<td>0.91 [ 0.05, 15.52 ]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>23</td>
<td>21</td>
<td>0.91 [ 0.05, 15.52 ]</td>
<td>100.0 %</td>
<td>0.91 [ 0.05, 15.52 ]</td>
</tr>
</tbody>
</table>

Total events: 1 (Metformin), 1 (Megestrol acetate)  
Heterogeneity: not applicable  
Test for overall effect: Z = 0.07 (P = 0.95)  
Test for subgroup differences: Not applicable

### Analysis 2.1. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as proliferative/secretory endometrium).

Review: Metformin for endometrial hyperplasia  
Comparison: 2 Metformin plus megestrol acetate versus megestrol acetate  
Outcome: 1 Regression of endometrial hyperplasia (with or without atypia) towards normal histology (defined here as proliferative/secretory endometrium)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin + MA</th>
<th>Megestrol acetate (MA)</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shan 2014</td>
<td>6/8</td>
<td>2/8</td>
<td>9.00 [ 0.94, 86.52 ]</td>
<td>100.0 %</td>
<td>9.00 [ 0.94, 86.52 ]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>8</td>
<td>8</td>
<td>9.00 [ 0.94, 86.52 ]</td>
<td>100.0 %</td>
<td>9.00 [ 0.94, 86.52 ]</td>
</tr>
</tbody>
</table>

Total events: 6 (Metformin + MA), 2 (Megestrol acetate (MA))  
Heterogeneity: not applicable  
Test for overall effect: Z = 1.90 (P = 0.057)  
Test for subgroup differences: Not applicable
### Analysis 2.2. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 2
Recurrence of endometrial hyperplasia.

**Review:** Metformin for endometrial hyperplasia

**Comparison:** 2 Metformin plus megestrol acetate versus megestrol acetate

**Outcome:** 2 Recurrence of endometrial hyperplasia

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin + MA n/N</th>
<th>Megestrol acetate n/N</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shan 2014</td>
<td>0/6</td>
<td>0/2</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>6</td>
<td>2</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
</tbody>
</table>

Total events: 0 (Metformin + MA), 0 (Megestrol acetate)

- Heterogeneity: not applicable
- Test for overall effect: not applicable
- Test for subgroup differences: Not applicable

---

### Analysis 2.3. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 3
Progression of endometrial hyperplasia to endometrial cancer.

**Review:** Metformin for endometrial hyperplasia

**Comparison:** 2 Metformin plus megestrol acetate versus megestrol acetate

**Outcome:** 3 Progression of endometrial hyperplasia to endometrial cancer

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin + MA n/N</th>
<th>Megestrol acetate n/N</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shan 2014</td>
<td>0/8</td>
<td>0/8</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>8</td>
<td>8</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
</tbody>
</table>

Total events: 0 (Metformin + MA), 0 (Megestrol acetate)

- Heterogeneity: not applicable
- Test for overall effect: not applicable
- Test for subgroup differences: Not applicable
Analysis 2.4. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 4 Hysterectomy rate.

Review: Metformin for endometrial hyperplasia
Comparison: 2 Metformin plus megestrol acetate versus megestrol acetate
Outcome: 4 Hysterectomy rate

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Metformin + MA</th>
<th>Megestrol acetate</th>
<th>Odds Ratio</th>
<th>Weight</th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Shan 2014</td>
<td>0/8</td>
<td>1/8</td>
<td>0.29 [0.01, 8.37]</td>
<td>100.0 %</td>
<td>0.29 [0.01, 8.37]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>8</td>
<td>8</td>
<td>100.0 %</td>
<td>0.29 [0.01, 8.37]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 0 (Metformin + MA), 1 (Megestrol acetate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable

Analysis 2.5. Comparison 2 Metformin plus megestrol acetate versus megestrol acetate, Outcome 5 Adverse effects during treatment.

Adverse effects during treatment

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shan 2014</td>
<td>3 patients in the metformin plus megestrol acetate group reported nausea that settled without medical treatment</td>
</tr>
</tbody>
</table>

APPENDICES

Appendix 1. Gynaecology and Fertility Specialised Register search strategy

From inception to 10 January 2017

Procit platform

Keywords CONTAINS "endometrial hyperplasia" or "endometrial proliferation" or "endometrial thickness" or "proliferation" or "hyperplasia" or Title CONTAINS "endometrial hyperplasia" or "endometrial proliferation" or "endometrial thickness" or "proliferation" or "hyperplasia"
AND

Keywords CONTAINS "metformin" or "glucophage" or Title CONTAINS "metformin" or "glucophage"

(20 hits)
Appendix 2. CENTRAL Register of Studies Online (CRSO) search strategy

Searched 10 January 2017
Web platform

#1 MESH DESCRIPTOR Endometrial Hyperplasia EXPLODE ALL TREES 108

#2 (Endometr* adj5 Hyperplas*):TI,AB,KY 373

#3 (endometri* adj5 ?proliferat*):TI,AB,KY 109

#4 #1 OR #2 OR #3 446

#5 MESH DESCRIPTOR Metformin EXPLODE ALL TREES 1777

#6 metformin:TI,AB,KY 4409

#7 glucophage:TI,AB,KY 32

#8 (dimethylbiguanidine or dimethylguanylguanidine):TI,AB,KY 1

#9 (dimethylbiguanidium or glucovance):TI,AB,KY 6

#10 #5 OR #6 OR #7 OR #8 OR #9 4410

#11 #4 AND #10 4

Appendix 3. MEDLINE search strategy

From 1946 to 10 January 2017
Ovid platform

1 exp Endometrial Hyperplasia/ (3592)

2 (endometri$ adj5 hyperplas$).tw. (4707)

3 (endometri$ adj3 ?proliferat$).tw. (2820)

4 or/1-3 (8286)

5 exp Metformin/ (11182)

6 metformin.tw. (15758)

7 glucophage.tw. (110)

8 (dimethylbiguanidine or dimethylguanylguanidine).tw. (4)

9 (dimethylbiguanidium or glucovance).tw. (18)

10 or/5-9 (17514)

11 4 and 10 (51)

12 randomized controlled trial.pt. (507659)
Appendix 4. Embase search strategy

From 1980 to 10 January 2017

Ovid platform

1 exp endometrium hyperplasia/ (6938)

2 (endometri$ adj5 hyperplas$).tw. (5824)

3 (endometri$ adj3 proliferat$).tw. (3376)

4 or/1-3 (11242)

5 exp metformin/ (47713)

6 metformin.tw. (23994)

7 glucophage.tw. (1571)

8 (dimethylbiguanidine or dimethylguanylguanidine).tw. (4)

9 (dimethylbiguanidium or glucovance).tw. (195)

10 or/5-9 (48540)

11 4 and 10 (138)

12 Clinical Trial/ (1019530)
Randomized Controlled Trial/ (472724)
exp randomization/ (84526)
Single Blind Procedure/ (28735)
Double Blind Procedure/ (138900)
Crossover Procedure/ (54650)
Placebo/ (326024)
Randomi?ed controlled trial$.tw. (153072)
Rct.tw. (23004)
random allocation.tw. (1649)
randomly.tw. (343380)
randomly allocated.tw. (26969)
allocated randomly.tw. (2221)
(allocated adj2 random).tw. (847)
Single blind$.tw. (18934)
Double blind$.tw. (174826)
((treble or triple) adj blind$).tw. (672)
placebo$.tw. (250674)
prospective study/ (394570)
or/12-30 (2008326)
case study/ (94777)
case report.tw. (327043)
abstract report/ or letter/ (994732)
or/32-34 (1407253)
31 not 35 (1956293)
(exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5761760)
36 31 not 37 (1831795)
Appendix 5. CINAHL search strategy
From 1961 to 10 January 2017
Ebsco platform
1. (MM "Endometrial Diseases+)") 3,905
2. TX (endometr* N5 hyperplas*) 329
3. TX (endometr* N3 proliferat*) 111
4. 1 OR 2 OR 3 4,184
5. (MM "Metformin") 1,959
6. TX Metformin 5,076
7. TX glucophage 36
8. TX (dimethylbiguanidium or glucovance) 6
9. 5 OR 6 OR 7 OR 8 5,080
10. 4 AND 9 18

Appendix 6. PubMed search strategy
Searched 10 January 2017
Web platform
1. Endometrial Hyperplasia[mh]
2. (endometri* and hyperplas*)[tw]
3. (endometri* and proliferat*)[tw]
4. or/1-3
5. Metformin[mh]
6. metformin[tw]
7. glucophage[tw]
8. (dimethylbiguanidine or dimethylguanylguanidine)[tw]
9. (dimethylbiguanidium or glucovance)[tw]
10. or/5-9
11. 4 and 10
12. randomized controlled trial[ptyp]
13. controlled clinical trial[ptyp]
14. randomized[tw]
15. randomized[tw]
16. placebo[tw]
17. randomly[tw]
18. trial[tw]
19. (crossover or cross-over or cross over)[tw]
20. or/12-20
21. animals[mh] not humans[mh]
22. 20 not 21
23. 11 and 22
Appendix 7. Google Scholar search strategy
Searched 10 January 2017
Web platform
Keywords include: “endometrium”, “endometrial”, “hyperplasia”, “proliferation”, “metformin”

Appendix 8. ClinicalTrials.gov search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)

Appendix 9. World Health Organization International Trials Registry Platform search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)

Appendix 10. OpenGrey search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)

Appendix 11. LILACS search strategy
Searched 10 January 2017
Web platform
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)

Contributions of Authors
WA and NC initiated the review; NC, TO, and HS drafted and finalised the background and objectives; JS, TO, and HS drafted and finalised the methods sections with assistance from CM. WA reviewed the final protocol. HS performed all searches. NC, TO, JS, and HS then screened titles and abstracts for potential inclusion. Two of NC, TO, JS, and HS assessed each paper for potential inclusion. JS performed searches of unpublished trials and contacted relevant authors. NC, TO, HS, and JS extracted data from included studies, with WA providing clinical interpretation of data. NC, TO, HS, JS, and CM drafted the review, and WA reviewed the final draft.
DECLARATIONS OF INTEREST
WA is a Clinical Associate Professor and a Consultant Gynaecologist at Queen's Medical Centre, at Nottingham, in the UK. He previously submitted an application to the Nottingham Clinical Trials Unit (in the process of developing a research grant application to the UK NIHR) to conduct a clinical trial comparing metformin with progesterone for treatment of endometrial hyperplasia. A systematic review was suggested to support the trial.

SOURCES OF SUPPORT

Internal sources
• No sources of support, UK.

External sources
• No sources of support, UK.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

1. In the protocol, we stated that for the outcomes regression of endometrial hyperplasia and progression to endometrial carcinoma, we would calculate Mantel-Haenszel odds ratios. In the review, we have added that if data are available, we will (in preference) calculate hazard ratios for the outcomes regression of endometrial hyperplasia, recurrence of endometrial hyperplasia, and progression to endometrial carcinoma, as hazard ratios include participants who dropped out of the study and therefore provide the best way to analyse these outcomes.

2. In the protocol, our objective was "To determine the efficacy and safety of metformin in treating women with endometrial hyperplasia." Upon editorial recommendation, we have changed this to "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia."